No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Two New EMPOWR™ Systems Designed To Accelerate Surgical Efficiency Introduced

Editor: What To Know

  • With more than 450,000 total hip arthroplasty (THA)1 and 75,000 unicompartmental knee arthroplasty (UKA)2 procedures performed each year in the United States, the EMPOWR Acetabular and Partial Knee Systems provide surgeons with a comprehensive and efficient solution for all THA and UKA approaches and settings.
  • P2™, a proprietary Titanium porous coating that aids in the apposition of bone, has shown on a legacy design the disappearance of zone 2 radiolucent lines at one year follow-up signifying osseointegration4,5.
  • EMPOWR system efficiency is driven by premium, intelligently designed single-tray instrumentation, resulting in up to a 50% reduction in storage and sterilization costs compared to other systems on the market3.

Two new EMPOWR™ systems, EMPOWR Acetabular™ and EMPOWR Partial Knee™ have been introduced by DJO.  Both systems are designed to restore healthy kinematics and optimize surgical procedure efficiencies by allowing implantation with a single tray.

With more than 450,000 total hip arthroplasty (THA)1 and 75,000 unicompartmental knee arthroplasty (UKA)2 procedures performed each year in the United States, the EMPOWR Acetabular and Partial Knee Systems provide surgeons with a comprehensive and efficient solution for all THA and UKA approaches and settings. Instrument efficiency makes these systems especially relevant for outpatient and ambulatory surgery center procedures where surgeons may place an even greater priority on cost minimization opportunities.

“We are building on the proven success, deep clinical research, and differentiated design technologies of the EMPOWR™ platform with the launch of these new systems,” noted Louis Vogt, VP of Sales & Marketing of DJO Surgical®. “DJO is committed to improving patient outcomes and surgeon success, and with just a single tray, these EMPOWR systems will enable surgeons to be more efficient and effective, especially in the rapidly growing outpatient setting.”

EMPOWR system efficiency is driven by premium, intelligently designed single-tray instrumentation, resulting in up to a 50% reduction in storage and sterilization costs compared to other systems on the market3. Streamlined, intuitive instrumentation was designed to improve surgical workflow by reducing turnover time and waste. “These EMPOWR advances support the acceleration of outpatient total joint procedures and the procedure migration to the ASC setting where surgeons increasingly rely on streamlined solutions,” Vogt said.

The EMPOWR Acetabular System design leverages anthropometric data and advanced material technologies to help restore healthy kinematics and individual patient anatomy. P2™, a proprietary Titanium porous coating that aids in the apposition of bone, has shown on a legacy design the disappearance of zone 2 radiolucent lines at one year follow-up signifying osseointegration4,5. HXe+™ liners are specifically designed for ball and socket kinematics and blended with vitamin E to significantly reduce oxidation and long-term wear6.

“I’ve been using the EMPOWR Primary Knee System® on patients for years, and I am extremely pleased with the early results of the EMPOWR Acetabular System,” said Dr. Douglas Padgett, Chief of Adult Reconstruction and Joint Replacement Service at the Hospital of Special Surgery in New York City and former President of The Hip Society. “The EMPOWR Acetabular System provides predictable biologic fixation with P2 in-growth coating and acetabular screw placement. Enhanced features such as reliable liner locking feature, larger diameter heads in smaller shells, and efficient one-tray design have made this implant my acetabular system of choice,” noted Padgett.

The EMPOWR Partial Knee™ was developed with the same advanced material technologies and joint restoration principles as the EMPOWR™ Knee Platform, one of the industry’s most modern total knee systems, which has been clinically validated to increase patient satisfaction7. The EMPOWR Partial Knee was also designed using anthropometric data to create anatomically shaped femoral and tibial components for comprehensive bone coverage in either medial or lateral compartments while minimizing the potential for overhang and maximizing natural motion.

“EMPOWR is the knee of choice for all of my primary total knee replacements. The addition of the EMPOWR Partial Knee allows me to provide the full continuum of care from isolated unicompartmental disease to complex primary/revision knees with associated bone loss,” said Dr. Scott Sporer, Professor, Orthopaedic Surgery at Rush University Medical Center and Midwest Orthopaedics at Rush in Chicago, IL. “The outstanding clinical outcomes and predictable kinematics within the EMPOWR line of implants has allowed countless patients in my practice to return to their active lifestyles. In this ever changing medical climate, DJO has delivered a system that provides one tray of intuitive instrumentation to aid in efficiency and cost savings,” noted Sporer.


References:

  1. https://orthoinfo.aaos.org/en/treatment/total-hip-replacement/
  2. SmartTrak – US Knee Replacement Procedures, 2019
  3. Based on calculation of no. of trays compared to DePuy Pinnacle and Zimmer Biomet G7. https://www.ajog.org/article/S0002-9378(16)30358-1/pdf for cost of sterilization
    https://www.corailpinnacle.net/sites/default/files/2018-10/DSEMJRC05181044%20PINNACLE%20Surgical%20Technique.pdf
    https://www.zimmerbiomet.com/content/dam/zimmer-biomet/medical-professionals/000-surgical-techniques/hip/2336.2-GLBL-en_G7%20Surgical%20Technique.pdf
    Based on calculation of no. of trays compared to Oxford Uni Knee.
    https://www.zimmerbiomet.com/content/dam/zimmer-biomet/medical-professionals/000-surgical-techniques/knee/oxford-partial-knee-microplasty-instrumentation-surgical-technique.pdf
  4. P2™ Testing Summary 0020327-001 Rev A 10/14. Laboratory testing does not necessarily indicate clinical performance.
  5. Zielinski M, Deckard E, Meneghini M. The fate of zone 2 radiolucencies in contemporary highly-porous acetabular components: not all designs perform equally. Poster session presented at: 2017 AAHKS Annual Meeting; Nov 2-5: Dallas, TX.
  6. e+™ testing data on file. Bench test results not necessarily indicative of clinical performance.
  7. “Replicating Native Knee Dual-Pivot Kinematics Improves Outcomes After Total Knee Arthroplasty. R. Michael Meneghini MD – ICJR South Presentation June 2018.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy